These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37296579)

  • 1. Evaluation of
    Lastraioli E; Bettiol A; Iorio J; Limatola E; Checcacci D; Parisi E; Bianchi C; Arcangeli A; Iannopollo M; Di Costanzo F; Di Lieto M
    Cells; 2023 May; 12(11):. PubMed ID: 37296579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Lastraioli E; Antonuzzo L; Fantechi B; Di Cerbo L; Di Costanzo A; Lavacchi D; Armenio M; Arcangeli A; Castiglione F; Messerini L; Di Costanzo F
    Oncol Lett; 2021 Jan; 21(1):15. PubMed ID: 33240421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
    Normanno N; Esposito Abate R; Lambiase M; Forgione L; Cardone C; Iannaccone A; Sacco A; Rachiglio AM; Martinelli E; Rizzi D; Pisconti S; Biglietto M; Bordonaro R; Troiani T; Latiano TP; Giuliani F; Leo S; Rinaldi A; Maiello E; Ciardiello F;
    Ann Oncol; 2018 Jan; 29(1):112-118. PubMed ID: 28950295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded Low Allele Frequency
    Loree JM; Dowers A; Tu D; Jonker DJ; Edelstein DL; Quinn H; Holtrup F; Price T; Zalcberg JR; Moore MJ; Karapetis CS; O'Callaghan CJ; Waring P; Kennecke HF; Hamilton SR; Kopetz S
    Clin Cancer Res; 2021 Jan; 27(1):52-59. PubMed ID: 33087330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series.
    Mahdi Y; Khmou M; Souadka A; Agouri HE; Ech-Charif S; Mounjid C; Khannoussi BE
    BMC Gastroenterol; 2023 Jun; 23(1):193. PubMed ID: 37277698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid biopsy for
    Güttlein L; Luca MR; Esteso F; Fresno C; Mariani J; Otero Pizarro M; Brest E; Starapoli S; Kreimberg K; Teves P; Mendoza Bertelli A; R Girotti M; Salanova R; O'Connor JM
    Future Oncol; 2022 Sep; 18(29):3277-3287. PubMed ID: 36004810
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report.
    Lastraioli E; Lavacchi D; Palmieri VE; Castiglione F; Messerini L; Di Costanzo F; Antonuzzo L
    Anticancer Drugs; 2020 Oct; 31(9):979-982. PubMed ID: 32889896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.
    Vivancos A; Aranda E; Benavides M; Élez E; Gómez-España MA; Toledano M; Alvarez M; Parrado MRC; García-Barberán V; Diaz-Rubio E
    Sci Rep; 2019 Jun; 9(1):8976. PubMed ID: 31222012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
    Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M
    Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.
    Holm M; Andersson E; Osterlund E; Ovissi A; Soveri LM; Anttonen AK; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A
    PLoS One; 2020; 15(11):e0239819. PubMed ID: 33237900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11).
    Sunakawa Y; Satake H; Usher J; Jaimes Y; Miyamoto Y; Nakamura M; Kataoka M; Shiozawa M; Takagane A; Terazawa T; Watanabe T; Ishiguro K; Tanaka C; Takeuchi M; Fujii M; Danenberg K; Danenberg PV; Lenz HJ; Sekikawa T; Ichikawa W
    ESMO Open; 2022 Jun; 7(3):100512. PubMed ID: 35688061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.
    Pinheiro M; Peixoto A; Rocha P; Veiga I; Pinto C; Santos C; Pinto P; Guerra J; Escudeiro C; Barbosa A; Silva J; Teixeira MR
    Int J Colorectal Dis; 2022 Apr; 37(4):895-905. PubMed ID: 35303157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival.
    Sayagués JM; Montero JC; Jiménez-Pérez A; Del Carmen S; Rodríguez M; Vidal Tocino R; Montero E; Sanz J; Abad M
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer.
    García-Foncillas J; Tabernero J; Élez E; Aranda E; Benavides M; Camps C; Jantus-Lewintre E; López R; Muinelo-Romay L; Montagut C; Antón A; López G; Díaz-Rubio E; Rojo F; Vivancos A
    Br J Cancer; 2018 Dec; 119(12):1464-1470. PubMed ID: 30467411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms.
    Bádon ES; Mokánszki A; Mónus A; András C; Méhes G
    Mol Cell Probes; 2023 Feb; 67():101891. PubMed ID: 36586518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
    Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.